Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Sotio Biotech Inc.
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05120271CT.gov BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myxoid/Round Cell Liposarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| gpc3-car-t cells (this asset) | Sotio Biotech Inc. | P1/2 | CCC · 48 |
| Cyclophosphamide | Sotio Biotech Inc. | P1/2 | CCC |
| Fludarabine | Sotio Biotech Inc. | P1/2 | CCC |
| Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells | USWM CT, LLC | P1 | CC |
| Ny-Eso-1 Tcr Redirected Autologous T Cell Product | University of Pennsylvania | P1 | CC |
Other indications for gpc3-car-t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P1/2 | CCC · 53 |
| Squamous Cell Lung Carcinoma | — | P1/2 | CCC · 48 |
| Cutaneous Neuroendocrine Carcinoma | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. gpc3-car-t cells in Myxoid/Round Cell Liposarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gpc3-car-t-cells-myxoidround-cell-liposarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →